


This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (Cancelled):

2. (Cancelled):

3. (Currently Amended): A glycinamide compound according to claim 1, selected from the compounds of formula II: [.]



wherein

Ar¹ is phenyl, pyridinyl, oxazolyl, isoxazolyl, pyrazolyl or imidazolyl;

Ar¹, Ar² are each, independently from one another, selected from is an aromatic hydrocarbon group hydrocarbons containing 6 to 14 carbon atoms or an and ethylenical unsaturated or aromatic heterocyclic group residues containing 3 to 10 carbon atoms and one or two hetero atoms, wherein said hetero atoms are each independently selected from N, O or and S; [.]

R⁸ is alkyl having 1 to 4 carbon atoms, alkoxy having 1 to 4 carbon atoms, Hal, CH₂Hal, CH(Hal)₂, perhaloalkyl having 1 to 4 carbon atoms, NO₂, (CH₂)ₙCN, (CH₂)ₙNR¹¹R¹², (CH₂)ₙCOR¹³, (CH₂)ₙCOOR¹¹, (CH₂)ₙCONR¹¹R¹², (CH₂)ₙSO₂NR¹¹R¹², or (CH₂)ₙS(O)ₙR¹³.

R⁸, R⁹ and R¹⁰ are each independently selected from H, A, cycloalkyl having

comprising 3 to 7 carbon atoms, Hal, CH_2Hal , $\text{CH}(\text{Hal})_2$, $\text{C}(\text{Hal})_3$, NO_2 , $(\text{CH}_2)_n\text{CN}$, $(\text{CH}_2)_n\text{NR}^{11}\text{R}^{12}$, $(\text{CH}_2)_n\text{OR}^{11}$, $(\text{CH}_2)_n\text{O}(\text{CH}_2)_k\text{NR}^{11}\text{R}^{12}$, $(\text{CH}_2)_n\text{COOR}^{12}$, $(\text{CH}_2)_n\text{CONR}^{11}\text{R}^{12}$, $(\text{CH}_2)_n\text{NR}^{11}\text{COR}^{13}$, $(\text{CH}_2)_n\text{NR}^{11}\text{CONR}^{11}\text{R}^{12}$, $(\text{CH}_2)_n\text{NR}^{11}\text{SO}_2\text{A}$, $(\text{CH}_2)_n\text{SO}_2\text{NR}^{11}\text{R}^{12}$, $(\text{CH}_2)_n\text{S}(\text{O})_n\text{R}^{13}$, $(\text{CH}_2)_n\text{OC}(\text{O})\text{R}^{13}$, $(\text{CH}_2)_n\text{COR}^{13}$, $(\text{CH}_2)_n\text{SR}^{11}$, $\text{CH}=\text{N-OA}$, $\text{CH}_2\text{CH}=\text{N-OA}$, $(\text{CH}_2)_n\text{NHOA}$, $(\text{CH}_2)_n\text{CH}=\text{N-R}^{11}$, $(\text{CH}_2)_n\text{OC}(\text{O})\text{NR}^{11}\text{R}^{12}$, $(\text{CH}_2)_n\text{NR}^{11}\text{COOR}^{12}$, $(\text{CH}_2)_n\text{N}(\text{R}^{11})\text{CH}_2\text{CH}_2\text{OR}^{13}$, $(\text{CH}_2)_n\text{N}(\text{R}^{11})\text{CH}_2\text{CH}_2\text{OCF}_3$, $(\text{CH}_2)_n\text{N}(\text{R}^{11})\text{C}(\text{R}^{13})\text{HCOR}^{12}$, $\text{C}(\text{R}^{13})\text{HCOR}^{12}$, $(\text{CH}_2)_n\text{N}(\text{R}^{11})\text{CH}_2\text{CH}_2\text{N}(\text{R}^{12})\text{CH}_2\text{COOR}^{12}$, $(\text{CH}_2)_n\text{N}(\text{R}^{11})\text{CH}_2\text{CH}_2\text{NR}^{11}\text{R}^{12}$, $\text{CH}=\text{CHCOOR}^{11}$, $\text{CH}=\text{CHCH}_2\text{NR}^{11}\text{R}^{12}$, $\text{CH}=\text{CHCH}_2\text{NR}^{11}\text{R}^{12}$, $\text{CH}=\text{CHCH}_2\text{OR}^{13}$, $(\text{CH}_2)_n\text{N}(\text{COOR}^{11})\text{COOR}^{12}$, $(\text{CH}_2)_n\text{N}(\text{CONH}_2)\text{COOR}^{11}$, $(\text{CH}_2)_n\text{N}(\text{CONH}_2)\text{CONH}_2$, $(\text{CH}_2)_n\text{N}(\text{CH}_2\text{CONH}_2)\text{COOR}^{11}$, $(\text{CH}_2)_n\text{N}(\text{CH}_2\text{CONH}_2)\text{CONH}_2$, $(\text{CH}_2)_n\text{CHR}^{13}\text{COR}^{11}$, $(\text{CH}_2)_n\text{CHR}^{13}\text{COOR}^{11}$, $(\text{CH}_2)_n\text{CHR}^{13}\text{CH}_2\text{OR}^{14}$, $(\text{CH}_2)_n\text{OCN}_\pm$ or and $(\text{CH}_2)_n\text{NCO}_\pm$ [[.]]

R^{11} , R^{12} are each independently selected from H, A, $(\text{CH}_2)_m\text{Ar}^3$ or and $(\text{CH}_2)_m\text{Het}$, or, in $\text{NR}^{11}\text{R}^{12}$, R^{11} and R^{12} form, together with the N-Atom they are bound to, a 5-, 6- or 7-membered heterocycle which optionally contains 1 or 2 additional hetero atoms, wherein said hetero atoms are each independently selected from N, O or and S₂ [[.]]

R^{13} , R^{14} are each independently selected from H, Hal, A, $(\text{CH}_2)_m\text{Ar}^4$ or and $(\text{CH}_2)_m\text{Het}$; [[.]]

A is selected from alkyl, alkenyl, cycloalkyl, alkylencycloalkyl, alkoxy or and alkoxyalkyl; [[.]]

Ar^3 , Ar^4 are each independently from one another an aromatic hydrocarbon group having residues comprising 5 to 12 which is are optionally substituted by one or more substituents, wherein said substituents are in each case independently

selected from A, Hal, NO₂, CN, OR¹⁵, NR¹⁵R¹⁶, COOR¹⁵, CONR¹⁵R¹⁶, NR¹⁵COR¹⁶, NR¹⁵CONR¹⁵R¹⁶, NR¹⁶SO₂A, COR¹⁵, SO₂R¹⁵R¹⁶, S(O)_uA, or and OOCR¹⁵; [[,]]

Het is a saturated, unsaturated or aromatic heterocyclic group residue which is optionally substituted by one or more substituents, wherein said substituents are in each case independently selected from A, Hal, NO₂, CN, OR¹⁵, NR¹⁵R¹⁶, COOR¹⁵, CONR¹⁵R¹⁶, NR¹⁵COR¹⁶, NR¹⁵CONR¹⁵R¹⁶, NR¹⁶SO₂A, COR¹⁵, SO₂R¹⁵R¹⁶, S(O)_uA, or and OOCR¹⁵; [[,]]

R¹⁵, R¹⁶ are each independently selected from H, A, or and (CH₂)_mAr⁵; [[,]]

Ar⁵ Ar⁶ is a 5- or 6-membered aromatic hydrocarbon which is optionally substituted by one or more substituents, wherein said substituents are in each case independently selected from methyl, ethyl, propyl, 2-propyl, tert.-butyl, Hal, CN, OH, NH₂, or and CF₃; [[,]]

k, n, m are independently of one another 0, 1, 2, 3, 4, or 5;

n is 0 or 1;

X is O, S, NR¹⁵, CHOR¹¹, CH₂, CH₂CH₂, OCH₂, CH₂O, OCH₂CH₂, or CH₂CH₂O; represents a bond or is (CR¹⁴R¹²)_h or (CHR¹⁴)_hQ(CHR¹²)_h

Q is selected from O, S, N-R¹⁵, (CHal₂)_j, (O-CHR¹⁸)_j, (CHR¹⁸-O)_j, CR¹⁸=CR¹⁹, (O-CHR¹⁸CHR¹⁹)_j, CHR¹⁸CHR¹⁹-O)_j, C=O, C=S, C=NR¹⁵, CH(OR¹⁵), C(OR¹⁷)(OR²⁰), C(=O)O, OC(=O), OC(=O)O, C(=)N(R¹⁵), N(R¹⁵)C(=O), OC(=O)N(R¹⁵), N(R¹⁵)C(=O)O, CH=N-O, CH=N-NR¹⁵, OC(O)NR¹⁵, NR¹⁵C(O)O, S=O, SO₂, SO₂NR¹⁵, or and NR¹⁵SO₂; [[,]]

h, i are independently from each other 0, 1, 2, 3, 4, 5 or 6; [[,]]

j is 1, 2, 3, 4, 5 or 6; [.,.]

Y is selected from O, S, NR²¹, C(R²²)-NO₂, C(R²²)-CN, or and C(CN); [.,.]

R²¹ is H, Hal, A, (CH₂)_mAr⁴ or and (CH₂)_mHet; [.,.]

R²² is H, A, (CH₂)_mAr³ or and (CH₂)_mHet; [.,.]

p is 1, 2 or 3;

p, r is are independently from one another 0, 1, 2, 3, 4 or 5; [.,.]

q is 0 or 1; 0, 1, 2, 3 or 4;


u is 0 or 2; 0, 1, 2 or 3;

and


Hal is in each case independently selected from F, Cl, Br or and I;

or a salt or solvate and the salts and solvates thereof.


4. (Currently Amended): A glycinamide compound according to claim 34, selected from the compounds of formula IIa, IIb, IIc, IID, IIe, IIf, IIg and IIh, [.]




MERCK-2971




IIb




IIc




IIId



IIe




IIIf



IIg

MERCK-2971



wherein

R⁸ is alkyl having 1 to 4 carbon atoms, alkoxy having 1 to 4 carbon atoms, Hal, CH₂Hal, CH(Hal)₂, C(Hal)₃, NO₂, (CH₂)_nCN, (CH₂)_nNR¹¹R¹², (CH₂)_nCOR¹³, (CH₂)_nCOOR¹¹, (CH₂)_nCONR¹¹R¹², (CH₂)_nSO₂NR¹¹R¹², or (CH₂)_nS(O)_uR¹³,

R⁸, R⁹ and R¹⁰ are independently selected from H, A, cycloalkyl comprising 3 to 7 carbon atoms, Hal, CH₂Hal, CH(Hal)₂, C(Hal)₃, NO₂, (CH₂)_nCN, (CH₂)_nNR¹¹R¹², (CH₂)_nOR¹¹, (CH₂)_nO(CH₂)_kNR¹¹R¹², (CH₂)_nCOOR¹², (CH₂)_nCONR¹¹R¹², (CH₂)_nNR¹¹COR¹³, (CH₂)_nNR¹¹CONR¹¹R¹², (CH₂)_nNR¹¹SO₂A, (CH₂)_nSO₂NR¹¹R¹², (CH₂)_nS(O)_uR¹³, (CH₂)_nOC(O)_uR¹³, (CH₂)_nCOR¹³, (CH₂)_nSR¹¹, CH=N-OA, CH₂CH=N-OA, (CH₂)_nNHOA, (CH₂)_nCH=N-R¹¹, (CH₂)_nOC(O)NR¹¹R¹², (CH₂)_nNR¹¹COOR¹², (CH₂)_nN(R¹¹)CH₂CH₂OR¹³, (CH₂)_nN(R¹¹)CH₂CH₂OCF₃, (CH₂)_nN(R¹¹)C(R¹³)HCOOR¹², C(R¹³)HCOR¹², (CH₂)_nN(R¹¹)CH₂CH₂N(R¹²)CH₂COOR¹², (CH₂)_nN(R¹¹)CH₂CH₂NR¹¹R¹², CH=CHCOOR¹¹, CH=CHCH₂NR¹¹R¹², CH=CHCH₂NR¹¹R¹², CH=CHCH₂OR¹³, (CH₂)_nN(COOR¹¹)COOR¹², (CH₂)_nN(CONH₂)COOR¹¹, (CH₂)_nN(CONH₂)CONH₂, (CH₂)_nN(CH₂COOR¹¹)COOR¹², (CH₂)_nN(CH₂CONH₂)COOR¹¹, (CH₂)_nN(CH₂CONH₂)CONH₂, (CH₂)_nCHR¹³COR¹¹, (CH₂)_nCHR¹³COOR¹¹, (CH₂)_nCHR¹³CH₂OR¹⁴, (CH₂)_nOCN and (CH₂)_nNCO,

R¹⁰ can also be H,

R¹¹, R¹² are each independently selected from H, A, (CH₂)_mAr³, or and (CH₂)_mHet, or, in NR¹¹R¹², R¹¹ and R¹² form, together with the N-Atom they are bound to, a 5-, 6- or 7-membered heterocycle which optionally contains 1 or 2 additional

MERCK-2971

hetero atoms, wherein said hetero atoms are independently selected from N, O or an S,

R^{13}, R^{14} are each independently selected from H, Hal, A, $(CH_2)_mAr^4$, or and $(CH_2)_mHet$,

A is selected from alkyl, alkenyl, cycloalkyl, alkylene cycloalkyl, alkoxy, or and alkoxyalkyl,

Ar^3, Ar^4 are each independently from one another an aromatic hydrocarbon group having residues comprising 5 to 12 carbon atoms which is are optionally substituted by one or more substituents, wherein said substituents are in each case independently selected from A, Hal, NO_2 , CN, OR^{15} , $NR^{15}R^{16}$, $COOR^{15}$, $CONR^{15}R^{16}$, $NR^{15}COR^{16}$, $NR^{15}CONR^{15}R^{16}$, $NR^{16}SO_2A$, COR^{15} , $SO_2R^{15}R^{16}$, $S(O)_nA$, or and $OOCR^{15}$,

Het is a saturated, unsaturated or aromatic heterocyclic group residue which is optionally substituted by one or more substituents, wherein said substituents are in each case independently selected from A, Hal, NO_2 , CN, OR^{15} , $NR^{15}R^{16}$, $COOR^{15}$, $CONR^{15}R^{16}$, $NR^{15}COR^{16}$, $NR^{15}CONR^{15}R^{16}$, $NR^{16}SO_2A$, COR^{15} , $SO_2R^{15}R^{16}$, $S(O)_nA$, or and $OOCR^{15}$,

R^{15}, R^{16} are each independently selected from a group consisting of H, A, or and $(CH_2)_mAr^5$,

Ar^5 is a 5- or 6-membered aromatic hydrocarbon which is optionally substituted by one or more substituents, wherein said substituents are in each case independently selected from methyl, ethyl, propyl, 2-propyl, tert.-butyl, Hal, CN, OH, NH_2 , or and CF_3 ,

n, m are independently of one another 0, 1, 2, 3, 4, or 5;

p is 0, 1, or 2, 0, 1, 2, 3, 4 or 5,

q is 0 or 1, 0, 1, 2, 3 or 4,

u is 0, 1, 2 or 3,



Y is selected from O, S, NR²¹, C(R²²)-NO₂, C(R²²)-CN, or and C(CN)₂,





R²¹ is H, Hal, A, (CH₂)_mAr⁴, or and (CH₂)_mHet,

R²² is H, A, (CH₂)_mAr³, or and (CH₂)_mHet,


or a salt or solvate and the salts and solvates thereof.

5. (Currently Amended): A glycaminamide compound according to claim + 3,
selected from






MERCK-2971



and



6. (Cancelled):
7. (Cancelled):
8. ((Cancelled):
9. (Cancelled):
10. (Previously Presented): A pharmaceutical composition comprising one or more compounds according to claim 1, and one or more additional compounds, selected from physiologically acceptable excipients, auxiliaries, adjuvants, carriers and other pharmaceutical active ingredients.
11. (Currently Amended): A process for the manufacture of a pharmaceutical composition comprising:
processing one or more compounds according to claim 1 and one or more compounds selected from the group consisting of carriers, excipients, auxiliaries and pharmaceutical active ingredients other than the compounds according to claim 1, by mechanical means into a dosage form pharmaceutical composition that is suitable as dosage form for application

and/or administration to a patient.

12. (Cancelled):

13. (Cancelled):

14. (Cancelled):

15. (Cancelled):

16. (Cancelled):

17. (Cancelled):

18. (Cancelled):

19. (Cancelled):

20. (Cancelled):

21. (Cancelled):

22. (Cancelled):

23. (Cancelled):

24. (Cancelled):


25. (Cancelled):

26. (Cancelled):

27. (Cancelled):

28. (Currently Amended): A method for producing a compound according to claim 3 of formula II, said method comprising:

reacting a compound of formula III



wherein

L^1 is Cl, Br, I, OH, a reactive esterified OH-group or a diazonium moiety, and

R^8 , Ar^1 , and Y are as defined in claim 3,

R^8 is selected from H, A, cycloalkyl comprising 3 to 7 carbon atoms, Hal, CH_2Hal , $\text{CH}(\text{Hal})_2$, $\text{C}(\text{Hal})_3$, NO_2 , $(\text{CH}_2)_n\text{CN}$, $(\text{CH}_2)_n\text{NR}^{+}\text{R}^{12}$, $(\text{CH}_2)_n\text{OR}^{+}$, $(\text{CH}_2)_n\text{O}(\text{CH}_2)_n\text{NR}^{+}\text{R}^{12}$, $(\text{CH}_2)_n\text{COOR}^{+}$, $(\text{CH}_2)_n\text{CONR}^{+}\text{R}^{12}$, $(\text{CH}_2)_n\text{NR}^{+}\text{COR}^{12}$, $(\text{CH}_2)_n\text{NR}^{+}\text{CONR}^{+}\text{R}^{12}$, $(\text{CH}_2)_n\text{NR}^{+}\text{SO}_2\text{A}$, $(\text{CH}_2)_n\text{SO}_2\text{NR}^{+}\text{R}^{12}$, $(\text{CH}_2)_n\text{S}(\text{O})_n\text{R}^{12}$, $(\text{CH}_2)_n\text{OC}(\text{O})\text{R}^{12}$, $(\text{CH}_2)_n\text{COR}^{12}$, $(\text{CH}_2)_n\text{SR}^{+}$, $\text{CH}=\text{N}-\text{OA}$, $\text{CH}_2\text{CH}=\text{N}-\text{OA}$, $(\text{CH}_2)_n\text{NHOA}$, $(\text{CH}_2)_n\text{CH}=\text{N}-\text{R}^{+}$, $(\text{CH}_2)_n\text{OC}(\text{O})\text{NR}^{+}\text{R}^{12}$, $(\text{CH}_2)_n\text{NR}^{+}\text{COOR}^{+}$, $(\text{CH}_2)_n\text{N}(\text{R}^{+})\text{CH}_2\text{CH}_2\text{OR}^{12}$, $(\text{CH}_2)_n\text{N}(\text{R}^{+})\text{CH}_2\text{CH}_2\text{OCF}_3$, $(\text{CH}_2)_n\text{N}(\text{R}^{+})\text{C}(\text{R}^{12})\text{HCOOR}^{+}$, $\text{C}(\text{R}^{12})\text{HCOOR}^{+}$, $(\text{CH}_2)_n\text{N}(\text{R}^{+})\text{CH}_2\text{CH}_2\text{N}(\text{R}^{12})\text{CH}_2\text{COOR}^{+}$, $(\text{CH}_2)_n\text{N}(\text{R}^{+})\text{CH}_2\text{CH}_2\text{NR}^{+}\text{R}^{12}$, $\text{CH}=\text{CHCOOR}^{+}$, $\text{CH}=\text{CHCH}_2\text{NR}^{+}\text{R}^{12}$, $\text{CH}=\text{CHCH}_2\text{NR}^{+}\text{R}^{12}$, $\text{CH}=\text{CHCH}_2\text{OR}^{12}$, $(\text{CH}_2)_n\text{N}(\text{COOR}^{+})\text{COOR}^{+}$, $(\text{CH}_2)_n\text{N}(\text{CONH}_2)\text{COOR}^{+}$, $(\text{CH}_2)_n\text{N}(\text{CONH}_2)\text{CONH}_2$, $(\text{CH}_2)_n\text{N}(\text{CH}_2\text{CONH}_2)\text{COOR}^{+}$, $(\text{CH}_2)_n\text{N}(\text{CH}_2\text{CONH}_2)\text{CONH}_2$,

MERCK-2971

$(CH_2)_nCHR^{13}COR^{14}$, $(CH_2)_nCHR^{13}COOR^{14}$, $(CH_2)_nCHR^{13}CH_2OR^{14}$,
 $(CH_2)_nOCN$ and $(CH_2)_nNCO$,

p — is 0, 1, 2, 3, 4 or 5;

Ar¹ — is selected from aromatic hydrocarbons containing 6 to 14 carbon atoms and ethylenical unsaturated or aromatic heterocyclic residues containing 3 to 10 carbon atoms and one or two hetero atoms, independently selected from N, O and S;

Y — is selected from O, S, NR²¹, C(R²²)-NO₂, C(R²²)-CN and C(CN)₂;

A — is selected from alkyl, alkenyl, cycloalkyl, alkylene cycloalkyl, alkoxy and alkoxyalkyl;

R¹¹, R¹² are independently selected from H, A, $(CH_2)_mAr^3$ and $(CH_2)_mHet$, or, in NR¹¹R¹², R¹¹ and R¹² form, together with the N Atom they are bound to, a 5, 6 or 7 membered heterocycle which optionally contains 1 or 2 additional hetero atoms, selected from N, O and S;

k, n, m are independently of one another 0, 1, 2, 3, 4, or 5;

R¹³, R¹⁴ are independently selected from H, Hal, A, $(CH_2)_mAr^4$ and $(CH_2)_mHet$,

Ar³, Ar⁴ are independently from one another aromatic hydrocarbon residues comprising 5 to 12 carbon atoms which are optionally substituted by one or more substituents, selected from A, Hal, NO₂, CN, OR¹⁵, NR¹⁵R¹⁶, COOR¹⁵, CONR¹⁵R¹⁶, NR¹⁵COR¹⁶, NR¹⁵-CONR¹⁵R¹⁶, NR¹⁶SO₂A, COR¹⁵, SO₂R¹⁵R¹⁶, S(O)₂A and OOCR¹⁵;

Het — is a saturated, unsaturated or aromatic heterocyclic residue which is

optionally substituted by one or more substituents, selected from A,
 Hal, NO_2 , CN, OR¹⁵, NR¹⁵R¹⁶, COOR¹⁵, CONR¹⁵R¹⁶, NR¹⁵COR¹⁶,
 NR¹⁵CONR¹⁵R¹⁶, NR¹⁶SO₂A, COR¹⁵, SO₂R¹⁵R¹⁶, S(O)_uA and
 OOCR¹⁵;

R¹⁵, R¹⁶ are independently selected from H, A, and $(\text{CH}_2)_m\text{Ar}^5$;


Ar⁵ is a 5- or 6-membered aromatic hydrocarbon which is optionally
 substituted by one or more substituents selected from methyl, ethyl,
 propyl, 2-propyl, tert-butyl, Hal, CN, OH, NH₂ and CF₃;

u is 0, 1, 2 or 3;

R²¹ is H, Hal, A, $(\text{CH}_2)_m\text{Ar}^4$ and $(\text{CH}_2)_m\text{Het}$;

R²² is H, A, $(\text{CH}_2)_m\text{Ar}^3$ and $(\text{CH}_2)_m\text{Het}$;

with a compound of formula IV,



wherein

L², L³ are independently from one another H or a metal ion, and

R⁹, q, X, Ar², R¹⁰ and r are as defined in claim 3,

R^9 and R^{10} are independent from one another selected from H, A, cycloalkyl comprising 3 to 7 carbon atoms, Hal, CH_2Hal , $CH(Hal)_2$, $C(Hal)_3$, NO_2 , $(CH_2)_nCN$, $(CH_2)_nNR^{11}R^{12}$, $(CH_2)_nOR^{13}$, $(CH_2)_nNR^{14}R^{12}$, $(CH_2)_nCOOR^{12}$, $(CH_2)_nCONR^{14}R^{12}$, $(CH_2)_nNR^{14}COR^{12}$, $(CH_2)_nNR^{14}CONR^{14}R^{12}$, $(CH_2)_nNR^{14}SO_2A$, $(CH_2)_nSO_2NR^{14}R^{12}$, $(CH_2)_nS(O)_nR^{13}$, $(CH_2)_nOC(O)R^{13}$, $(CH_2)_nCOR^{13}$, $(CH_2)_nSR^{14}$, $CH=N-OA$, $CH_2CH=N-OA$, $(CH_2)_nNHOA$, $(CH_2)_nCH=N-R^{14}$, $(CH_2)_nOC(O)NR^{14}R^{12}$, $(CH_2)_nNR^{14}COOR^{12}$, $(CH_2)_nN(R^{14})CH_2CH_2OR^{13}$, $(CH_2)_nN(R^{14})CH_2CH_2OCF_3$, $(CH_2)_nN(R^{14})C(R^{12})HCOR^{12}$, $C(R^{12})HCOR^{12}$, $(CH_2)_nN(R^{14})CH_2CH_2N(R^{12})CH_2COOR^{12}$, $(CH_2)_nN(R^{14})CH_2CH_2NR^{14}R^{12}$, $CH=CHCOOR^{14}$, $CH=CHCH_2NR^{14}R^{12}$, $CH=CHCH_2NR^{14}R^{12}$, $CH=CHCH_2OR^{12}$, $(CH_2)_nN(COOR^{14})COOR^{12}$, $(CH_2)_nN(CONH_2)COOR^{14}$, $(CH_2)_nN(CONH_2)CONH_2$, $(CH_2)_nN(CH_2COOR^{14})COOR^{12}$, $(CH_2)_nN(CH_2CONH_2)COOR^{14}$, $(CH_2)_nN(CH_2CONH_2)CONH_2$, $(CH_2)_nCHR^{12}COR^{14}$, $(CH_2)_nCHR^{12}COOR^{14}$, $(CH_2)_nCHR^{12}CH_2OR^{14}$, $(CH_2)_nOCN$ and $(CH_2)_nNCO$,

q is 0, 1, 2, 3, or 4;

X represents a bond or is $(CR^{14}R^{12})_n$ or $(CHR^{14})_n-Q-(CHR^{12})_n$,

Ar^2 is selected from aromatic hydrocarbons containing 6 to 14 carbon atoms and ethylenical unsaturated or aromatic heterocyclic residues containing 3 to 10 carbon atoms and one or two hetero atoms, independently selected from N, O and S,

r is 0, 1, 2, 3, 4 or 5, and

h, i are independently from each other 0, 1, 2, 3, 4, 5 or 6;

r — is 0, 1, 2, 3, 4 or 5

and optionally isolating and/or treating the compound of formula II obtained by said reaction with an acid, to obtain the salt thereof.

29. (Cancelled):

30. (Cancelled):

31. (Currently Amended): A compound according to claim 3, wherein Ar^1 is phenyl, pyridinyl, oxazolyl, isoxazolyl, pyrazolyl or imidazolyl, preferably phenyl, pyridinyl or isoxazolyl and especially phenyl or oxazolyl,

p — is 1, 2 or 3;

R^8 — is selected from the group consisting of alkyl comprising 1 to 4 carbon atoms, alkoxy comprising 1 to 4 carbon atoms, Hal , CH_2Hal , $\text{CH}(\text{Hal})_2$, perhaloalkyl comprising 1 to 4 carbon atoms, NO_2 , $(\text{CH}_2)_n\text{CN}$, $(\text{CH}_2)_n\text{NR}^{11}\text{R}^{12}$, $(\text{CH}_2)_n\text{COR}^{13}$, $(\text{CH}_2)_n\text{COOR}^{14}$, $(\text{CH}_2)_n\text{CONR}^{15}\text{R}^{16}$, $(\text{CH}_2)_n\text{SO}_2\text{NR}^{17}\text{R}^{18}$ and $(\text{CH}_2)_n\text{S}(\text{O})_n\text{R}^{19}$, wherein

n — is 0 or 1;

u — is 0 or 2;

q — is 0 or 1, and

X — is O , S , NR^{15} , CHOR^{14} , CH_2 , CH_2CH_2 , OCH_2 , CH_2O , OCH_2CH_2 , or $\text{CH}_2\text{CH}_2\text{O}$.

32. (Previously Presented): A compound according to claim 31, wherein A² is phenyl or pyridinyl.

33. (Previously Presented): A compound according to claim 31, wherein X is O or S.

34. (Previously Presented): A compound according to claim 31, wherein Y is O or S.

35. (Previously Presented): A compound according to claim 31, wherein A¹ is phenyl or oxazolyl.

36. (Previously Presented): A compound according to claim 31, wherein A² is pyridinyl.

37. (Previously Presented): A compound according to claim 31, wherein X is O.

38. (Previously Presented): A compound according to claim 31, wherein Y is O.

39. (New): A compound according to claim 31, wherein A¹ is phenyl.

40. (New): A compound according to claim 3, wherein A is alkyl having 1 to 10 carbon atoms, allyl, 2-butenyl, 3-butenyl, isobutanyl, sec-butanyl, 4-pentenyl, isopentenyl, 5-hexenyl, cycloalkyl having 3 to 7 carbon atoms, alkylene cycloalkyl having 5 to 10 carbon atoms, alkoxy having 1 to 10 carbon atoms, or C_uH_{2u+1}-O-(CH₂)_v wherein u is 1 to 6 and v is 1 to 6.

41. (New): A compound according to claim 4, wherein A is alkyl having 1 to 10 carbon atoms, allyl, 2-butenyl, 3-butenyl, isobutanyl, sec-butanyl, 4-pentenyl, isopentenyl, 5-hexenyl, cycloalkyl having 3 to 7 carbon atoms, alkylene cycloalkyl having 5 to 10 carbon atoms, alkoxy having 1 to 10 carbon atoms, or C_uH_{2u+1}-O-(CH₂)_v wherein u is 1 to 6 and v is 1 to 6.

42. (New): A compound according to claim 31, wherein A is alkyl having 1 to 10 carbon atoms, allyl, 2-butenyl, 3-butenyl, isobutanyl, sec-butanyl, 4-pentenyl, isopentenyl, 5-hexenyl, cycloalkyl having 3 to 7 carbon atoms, alkylene cycloalkyl having 5 to 10 carbon atoms, alkoxy having 1 to 10 carbon atoms, or $C_uH_{2u+1}-O-(CH_2)_v$ wherein u is 1 to 6 and v is 1 to 6.

43. (New): A compound according to claim 35, wherein A is alkyl having 1 to 10 carbon atoms, allyl, 2-butenyl, 3-butenyl, isobutanyl, sec-butanyl, 4-pentenyl, isopentenyl, 5-hexenyl, cycloalkyl having 3 to 7 carbon atoms, alkylene cycloalkyl having 5 to 10 carbon atoms, alkoxy having 1 to 10 carbon atoms, or $C_uH_{2u+1}-O-(CH_2)_v$ wherein u is 1 to 6 and v is 1 to 6.

44. (New): A compound according to claim 39, wherein A is alkyl having 1 to 10 carbon atoms, allyl, 2-butenyl, 3-butenyl, isobutanyl, sec-butanyl, 4-pentenyl, isopentenyl, 5-hexenyl, cycloalkyl having 3 to 7 carbon atoms, alkylene cycloalkyl having 5 to 10 carbon atoms, alkoxy having 1 to 10 carbon atoms, or $C_uH_{2u+1}-O-(CH_2)_v$ wherein u is 1 to 6 and v is 1 to 6.

45. (New): A compound according to claim 31, wherein A^2 is pyridinyl and X is O.

46. (New): A compound according to claim 35, wherein A^2 is pyridinyl and X is O.

47. (New): A compound according to claim 39, wherein A^2 is pyridinyl and X is O.

48. (New): A compound according to claim 42, wherein A^2 is pyridinyl and X is O.

49. (New): A compound according to claim 43, wherein A^2 is pyridinyl and X is O.

50. (New): A compound according to claim 44, wherein A² is pyridinyl and X is O.